These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26578723)

  • 1. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.
    Goldwirt L; Chami I; Feugeas JP; Pages C; Brunet-Possenti F; Allayous C; Baroudjian B; Madelaine I; Sauvageon H; Mourah S; Lebbé C
    Ann Oncol; 2016 Feb; 27(2):363-4. PubMed ID: 26578723
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al.
    Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Saiag P; Funck-Brentano C
    Ann Oncol; 2016 Feb; 27(2):364-5. PubMed ID: 26578725
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.
    Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Funck-Brentano C; Saiag P
    Ann Oncol; 2015 Jul; 26(7):1470-5. PubMed ID: 25899783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
    Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
    J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined inhibition of BRAF and MEK in melanoma patients.
    Infante JR; Swanton C
    Lancet Oncol; 2014 Aug; 15(9):908-10. PubMed ID: 25037140
    [No Abstract]   [Full Text] [Related]  

  • 6. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
    Kaplan FM; Mastrangelo MJ; Aplin AE
    J Invest Dermatol; 2010 Nov; 130(11):2669-71. PubMed ID: 20574441
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
    Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
    Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 9. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
    Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
    Perampaladas K; Hay N; Rinaldi F; Robertson J; Adam J
    Lancet Oncol; 2013 Jan; 14(1):20-1. PubMed ID: 23401870
    [No Abstract]   [Full Text] [Related]  

  • 13. Concerns regarding BRAF testing algorithm: reply from authors.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Nov; 169(5):1168-70. PubMed ID: 23855556
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract]   [Full Text] [Related]  

  • 18. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 19. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

  • 20. Zosteriform type in-transit metastasis of melanoma.
    Tas F
    Indian J Med Res; 2016 Jul; 144(1):143. PubMed ID: 27834341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.